The potential role of anticoagulant therapy for the secondary prevention of ischemic events post-acute coronary syndrome

A. C. Camuglia, K. E. Waddell-Smith, C. J. Hammett, P. E. Aylward

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)


The use of dual antiplatelet therapy has led to a substantial reduction in ischemic events post-acute coronary syndrome (ACS). Despite this, recurrent event rates remain high. Recent research has combined antiplatelet with anticoagulant therapy to reduce recurrent event rates further. Compared with standard medical therapy, rivaroxaban demonstrated improved efficacy outcomes and significantly reduced mortality after an ACS. Although clear benefits of novel oral anticoagulants post-ACS have been proven, concerns regarding bleeding are still a barrier to widespread use. This review explores key trials of dual antiplatelet therapy and examines the latest research in anticoagulation aiming to optimize clinical outcomes post-ACS.

Original languageEnglish
Pages (from-to)2151-2167
Number of pages17
JournalCurrent Medical Research and Opinion
Issue number11
Publication statusPublished or Issued - 1 Nov 2014


  • ACS
  • Acute coronary syndrome
  • Anticoagulants
  • Antiplatelets
  • Rivaroxaban

ASJC Scopus subject areas

  • Medicine(all)

Cite this